AWARENESS OF RIBAVIRIN THERAPY AMONG DENTAL STUDENTS
DOI:
https://doi.org/10.61841/cjp6a751Keywords:
Crownroot ratio; fixed partial denture; Probing depthAbstract
The aim of this study is to evaluate the abutment teeth selection in fixed partial denture (FPD) done by undergraduate students. For this, patient records of those who underwent replacement of missing teeth with fixed partial dentures were collected. A total of 50 patient radiographs were evaluated. The data on the following parameters: gender and age of the patient, crown root ratio, pocket depth, mobility, axial alignment of the abutment tooth, existing caries and periapical lesion or pulpal involvement, and alveolar ridge form were collected. The data was tabulated in an Excel sheet. After data collection, descriptive statistical analysis was done in SPSS software. In the current study, the most prevalent gender in the study population to undergo FPD treatment was males (66%) rather than females (34%). The most prevalent age group opting for FPD treatment was between 41 and 50 years (52%). 38% of the evaluated FPD abutments had a crown-root ratio of 1:1, and 40% of the abutments chosen for FPD construction were detected to have caries. A periapical lesion was present in 13% of the abutment teeth evaluated. Axial alignment of the tooth showed mostly normal alignment, representing 65%; pulpal involvement and root canal treatment were done in 17% of the evaluated abutments. The alveolar ridge form of the evaluated patients showed a flat ridge (58%). The present study shows appropriate parameters that have to be evaluated by undergraduate students during abutment selection for treatment planning of FPD
Downloads
References
1. Arumugam, S., & Watanabe, K. (2017). Japanese Kampo Medicines for the Treatment of Common
Diseases: Focus on Inflammation. Academic Press.
2. Bierman, S. M., Kirkpatrick, W., & Fernandez, H. (1981). Clinical Efficacy of Ribavirin in the Treatment
of Genital Herpes simplex Virus Infection. In Chemotherapy (Vol. 27, Issue 2, pp. 139–145).
https://doi.org/10.1159/000237969
3. Cohen, A., Togo, Y., Khakoo, R., Waldman, R., & Sigel, M. (1976). Comparative Clinical and Laboratory
Evaluation of the Prophylactic Capacity of Ribavirin, Amantadine Hydrochloride, and Placebo in Induced
Human Influenza Type A. In Journal of Infectious Diseases (Vol. 133, Issue Supplement 2, pp. A114–
A120). https://doi.org/10.1093/infdis/133.supplement_2.a114
4. Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y., Hong, Z., Andino, R., & Cameron, C. E. (2000).
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine, 6(12),
1375–1379.
5. Graci, J. D., & Cameron, C. E. (2006). Mechanisms of action of ribavirin against distinct viruses. Reviews
in Medical Virology, 16(1), 37–48.
6. Hahn, F. E. (2012). Modes and Mechanisms of Microbial Growth Inhibitors. Springer Science & Business
Media.
7. Paeshuyse, J., Dallmeier, K., & Neyts, J. (2011). Ribavirin for the treatment of chronic hepatitis C virus
infection: a review of the proposed mechanisms of action. Current Opinion in Virology, 1(6), 590–598.
8. Parker, W. B. (2005). Metabolism and antiviral activity of ribavirin. In Virus Research (Vol. 107, Issue 2,
pp. 165–171). https://doi.org/10.1016/j.virusres.2004.11.006
9. Schröder, C. (1982). R. A. Smith and W. Kirkpatrick (Editors), Ribavirin — A Broad Spectrum Antiviral
Agent. 237 S., 108 Abb., 82 Tab. New York—London—Toronto—Sydney—San Francisco 1980.
Academic Press. $ 21.00. In Zeitschrift für allgemeine Mikrobiologie (Vol. 22, Issue 2, pp. 152–152).
https://doi.org/10.1002/jobm.3630220219
10. Schröder, C. (2007). R. A. Smith and W. Kirkpatrick (Editors), Ribavirin - A Broad Spectrum Antiviral
Agent. 237 S., 108 Abb., 82 Tab. New York-London-Toronto-Sydney-San Francisco 1980. Academic
Press. $ 21.00. In Zeitschrift für allgemeine Mikrobiologie (Vol. 22, Issue 2, pp. 152–152).
https://doi.org/10.1002/jobm.19820220219
11. Smith, C. B., Charette, R. P., Fox, J. P., Cooney, M. K., & Hall, C. E. (1980). Lack of Effect of Oral
Ribavirin in Naturally Occurring Influenza A Virus (H1N1) Infection. In Journal of Infectious Diseases
(Vol. 141, Issue 5, pp. 548–554). https://doi.org/10.1093/infdis/141.5.548
12. Snell, N. J. C. (2001). Ribavirin - current status of a broad spectrum antiviral agent. In Expert Opinion on
Pharmacotherapy (Vol. 2, Issue 8, pp. 1317–1324). https://doi.org/10.1517/14656566.2.8.1317
13. Togo, Y., & McCracken, E. A. (1976). Double-Blind Clinical Assessment of Ribavirin (Virazole) in the
Prevention of Induced Infection with Type B Influenza Virus. In Journal of Infectious Diseases (Vol. 133,
Issue Supplement 2, pp. A109–A113). https://doi.org/10.1093/infdis/133.supplement_2.a109
14. Ventre, K., & Randolph, A. G. (2007). Ribavirin for respiratory syncytial virus infection of the lower
respiratory tract in infants and young children. Cochrane Database of Systematic Reviews,1, CD000181.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
